Gold nanoparticles and radiofrequency in experimental models for hepatocellular carcinoma

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 10, Issue 6, 2014, Pages 1121-1130

  Raoof, Mustafa ^a   Corr, Stuart J ^a,b   Zhu, Cihui ^a   Cisneros, Brandon T ^a,b   Kaluarachchi, Warna D ^a   Phounsavath, Sophia ^a,b   Wilson, Lon J ^b   Curley, Steven A ^a,c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b RICE UNIVERSITY   (United States)

^c Rice University   (United States)

Author keywords

Gemcitabine; Hepatocellular; Hyperthermia; Nanoparticle; Radiofrequency

Indexed keywords

BIOLOGICAL MATERIALS; CELL DEATH; METAL NANOPARTICLES; NANOCONJUGATES; NANOPARTICLES;

ANIMAL EXPERIMENTS; EXPERIMENTAL MODELS; GEMCITABINE; HEPATOCELLULAR; HEPATOCELLULAR CARCINOMA; HYPERTHERMIA; LOADING EFFICIENCY; RADIO FREQUENCIES;

GOLD;

CETUXIMAB; GEMCITABINE; GOLD NANOPARTICLE; DEOXYCYTIDINE; GOLD; METAL NANOPARTICLE; MONOCLONAL ANTIBODY; NANOCONJUGATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CARCINOMA CELL; CELL PROLIFERATION; CELL SURFACE; CHEMOSENSITIZATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SAFETY; HUMAN; HUMAN CELL; HYPERTHERMIC THERAPY; IN VITRO STUDY; LIVER CELL CARCINOMA; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PH; RADIATION EXPOSURE; RADIOFREQUENCY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CARCINOMA, HEPATOCELLULAR; CHEMISTRY; DRUG EFFECTS; LIVER; LIVER NEOPLASMS; PATHOLOGY; THERMOTHERAPY; TUMOR CELL LINE;

ANIMALIA;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CETUXIMAB; DEOXYCYTIDINE; DRUG DELIVERY SYSTEMS; GOLD; HUMANS; HYPERTHERMIA, INDUCED; LIVER; LIVER NEOPLASMS; METAL NANOPARTICLES; MICE, INBRED BALB C; NANOCONJUGATES;

EID: 84905247304     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2014.03.004     Document Type: Article

References (25)

1. Field S.B., Bleehen N.M. Hyperthermia in the treatment of cancer. Cancer Treat Rev 1979, 6(2):63-94.
2. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., et al. Sorafenib in advanced hepatocellular carcinoma (vol 359, pg 378, 2008). New England Journal of Medicine 2008, 359(23):2508.
3. Cherukuri P., Glazer E.S., Curleya S.A. Targeted hyperthermia using metal nanoparticles. Advanced Drug Delivery Reviews 2010, 62(3):339-345.
4. Corr S.J., Raoof M., Mackeyev Y., Phounsavath S., Cheney M.A., Cisneros B.T., et al. Citrate-capped gold nanoparticle electrophoretic heat production in response to a time-varying radiofrequency electric field. J Phys Chem 2012, 116:24380-24389.
5. Gannon C.J., Cherukuri P., Yakobson B.I., Cognet L., Kanzius J.S., Kittrell C., et al. Carbon nanotube-enhanced thermal destruction of cancer cells in a noninvasive radiofrequency field. Cancer 2007, 110(12):2654-2665.
6. Glazer E.S., Zhu C., Massey K.L., Thompson C.S., Kaluarachchi W.D., Hamir A.N., et al. Noninvasive radiofrequency field destruction of pancreatic adenocarcinoma xenografts treated with targeted gold nanoparticles. Clin Cancer Res 2011, 16(23):5712-5721.
7. Hanson G.W., Patch S.K. Optimum electromagnetic heating of nanoparticle thermal contrast agents at rf frequencies. Journal of Applied Physics 2009, 106(5):1141-1149.
8. Kruse D.E., Stephens D.N., Lindfors H.A., Ingham E.S., Paoli E.E., Ferrara K.W. A radio-frequency coupling network for heating of citrate-coated gold nanoparticles for cancer therapy: design and analysis. Ieee Transactions on Biomedical Engineering 2011, 58(7):2002-2012.
9. Ghosh P., Han G., De M., Kim C.K., Rotello V.M. Gold nanoparticles in delivery applications. Advanced Drug Delivery Reviews 2008, 60(11):1307-1315.
10. Mandal S., Bakeine G.J., Krol S., Ferrari C., Clerici A.M., Zonta C., et al. Design, development and characterization of multi-functionalized gold nanoparticles for biodetection and targeted boron delivery in BNCT applications. Applied Radiation and Isotopes 2011, 69(12):1692-1697.
11. Pissuwan D., Niidome T., Cortie M.B. The forthcoming applications of gold nanoparticles in drug and gene delivery systems. Journal of Controlled Release 2011, 149(1):65-71.
12. Patra C.R., Bhattacharya R., Wang E.F., Katarya A., Lau J.S., Dutta S., et al. Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent. Cancer Research 2008, 68(6):1970-1978.
13. Kumar S., Aaron J., Sokolov K. Directional conjugation of antibodies to nanoparticles for synthesis of multiplexed optical contrast agents with both delivery and targeting moieties. Nature Protocols 2008, 3(2):314-320.
14. Lanz C., Fruh M., Thormann W., Cerny T., Lauterburg B.H. Rapid determination of gemcitabine in plasma and serum using reversed-phase HPLC. Journal of Separation Science 2007, 30(12):1811-1820.
15. Raoof M., Corr S.J., Kaluarachchi W.D., Massey K.L., Briggs K., Zhu C., et al. Stability of antibody-conjugated gold nanoparticles in the endo-lysosomal nanoenvironment: Implications for non-invasive radiofrequency-based cancer therapy. Nanomedicine 2011.
16. Bhattacharyya S., Bhattacharya R., Curley S., McNiven M.A., Mukherjee P. Nanoconjugation modulates the trafficking and mechanism of antibody induced receptor endocytosis. Proceedings of the National Academy of Sciences of the United States of America 2010, 107(33):14541-14546.
17. Glazer E.S., Zhu C., Hamir A.N., Borne A., Thompson C.S., Curley S.A. Biodistribution and acute toxicity of naked gold nanoparticles in a rabbit hepatic tumor model. Nanotoxicology 2011, 5(4):459-468.
18. Higby G.J. Gold in medicine: a review of its use in the West before 1900. Gold Bull 1982, 15(4):130-140.
19. Yang T.S., Lin Y.C., Chen J.S., Wang H.M., Wang C.H. Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer 2000, 89(4):750-756.
20. Van Bree C., Beumer C., Rodermond H.M., Haveman J., Bakker P.J.M. Effectiveness of 2',2' difluorodeoxycytidine (Gemcitabine) combined with hyperthermia in rat R-1 rhabdomyosarcoma in vitro and in vivo. International Journal of Hyperthermia 1999, 15(6):549-556.
21. Vertrees R.A., Das G.C., Popov V.L., Coscio A.M., Goodwin T.J., Logrono R., et al. Synergistic interaction of hyperthermia and gemcitabine in lung cancer. Cancer Biology & Therapy 2005, 4(10):1144-1153.
22. Buckley A.F., Burgart L.J., Sahai V., Kakar S. Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma. Am J Clin Pathol 2008, 129(2):245-251.
23. Perrault S.D., Walkey C., Jennings T., Fischer H.C., Chan W.C.W. Mediating tumor targeting efficiency of nanoparticles through design. Nano Letters 2009, 9(5):1909-1915.
24. FDA: oncology tools - dose calculator [February 21, 2013]; Available from:. http://www.accessdata.fda.gov/scripts/cder/onctools/animalquery.cfm.
25. Raoof M., Cisneros B.T., Corr S.J., Palalon F., Curley S.A., Koshkina N.V. Tumor selective hyperthermia induced by short-wave capacitively-coupled RF electric-fields. PLoS One 2013, 8(7):e68506.